「Pneumococcus」の版間の差分

提供: Vaccipedia | Resources for Vaccines, Tropical medicine and Travel medicine
ナビゲーションに移動 検索に移動
 
(同じ利用者による、間の13版が非表示)
24行目: 24行目:
 
===History of Pneumococcal vaccines in Japan===
 
===History of Pneumococcal vaccines in Japan===
 
{|class="wikitable"
 
{|class="wikitable"
 +
|+''Table updated on 25th Aug 2023''
 
|-
 
|-
!
+
!style="width:4em" rowspan="2"|Year
!style="width:10em;"|Brand name
+
!style="width:12em"|PPSV23
!style="width:10em;"|Approval for children
+
!style="width:12em"|PCV7
!style="width:10em;"|Introduction to childhood routine immunization
+
!style="width:12em"|PCV13
!style="width:10em;"|Approval for adults
+
!style="width:12em"|PCV15
!style="width:10em;"|Introduction to adult routine immunization
+
!style="width:12em"|PCV20
!Note
 
 
|-
 
|-
!PPSV23
+
!Pneumovax NP||Prevenar||Prevenar13||Vaxneuvance||
|ニューモバックスNP<br>Pneumovax NP
 
|1988(昭和63年)<br>≥ 2 y/o
 
|N/A<sup>†</sup>
 
|1988(昭和63年)
 
|2014(平成26年)<br>only for all 65 y/o or 60-64 with specific conditions<sup>†</sup>
 
 
|-
 
|-
!PCV7
+
!1988<br>昭和63
|プレベナー<br>Prevenar
+
|'''Approved'''<br>- 2yr≤<br>'''''Covered by Public Health Insurance'''''<br>- Asplenia|| || || || |
|2009(平成21年)
 
|2010(平成22年)
 
|N/A
 
|M/A
 
|Sales terminated and switched to PCV13 in 2013
 
 
|-
 
|-
!PCV13
+
!2009<br>平成21
|プレベナー13<br>Prevenar 13
+
| ||'''Approved'''<br>- 2mo≤ ≤9yr|| || ||
|2013(平成25年)
 
|2013(平成25年)
 
|2014(平成26年)≥ 65 y/o<br>
 
2020(平成28年) people at high risk of IPD irrespective of age
 
|N/A
 
|
 
 
|-
 
|-
!PCV15
+
!2010<br>平成22
|バクニュバンス<br>Vaxneuvance
+
| ||'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| || ||
|2023(令和5年)
+
|-
|N/A as of 2023
+
!2013<br>平成25
|2022(令和4年) people at high risk of IPD irrespective of age
+
| ||'''Terminated''' and switched to PCV13||'''Approved'''<br>- 2mo≤ <6yr<br>'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| ||
|
+
|-
 +
!2014<br>平成26
 +
|'''''Routinized'''''<br>- at 65yr<br>- 60-64yr with specific chronic conditions|| ||'''Approved'''<br>- 65yr≤ at risk of IPD|| ||
 +
|-
 +
!2020<br>令和2
 +
| || ||'''Approved'''<br>- 6yr≤ at risk of IPD|| ||
 +
|-
 +
!2022<br>令和4
 +
| || || ||'''Approved'''<br>- elderly<br>- adults at risk of IPD||
 +
|-
 +
!2023<br>令和5
 +
| || || ||'''Approved'''<br>- 2mo≤||''Submitted for approval''
 +
|-
 +
! !!PPSV23!!PCV7!!PCV13!!PCV15!!PCV20
 
|}
 
|}
  
†covered by Public Health Insurance for asplenia
+
===Efficacy of pneumococcal vaccines===
 +
 
 +
===Effectiveness of pneumococcal vaccines===
 +
 
 +
===Effectiveness against colonization===
 +
 
 +
==Serotype replacement==
 +
 
 +
==Overwhelming Post-Splenectomy Infection (OPSI) and pnuemococcus==

2023年9月29日 (金) 22:31時点における最新版

Navigation Menu Vac logo.png
General issues of Vaccine
Cold chain
Correlates of Protection
Vaccines for Asplenia
Vaccines for Pregnant women
Vaccines for Immunocompromised hosts
Vaccine hesitancy
Additional materials of vaccine
General issues of Tropical med.
Definition of Tropical Medicine
Matrices of tropical infection
General issues of Helminths
Neglected Tropical Diseases
Sexually-transmitted infections
Non-Communicable Diseases
Maternal health and contraception
Child health
Malnutrition and Micronutrient
Eosinophilia
Fever in the tropics
Diarrhea in the tropics
Anemia in the tropics
Dermatology in the tropics
Ophthalmology in the tropics
Neurology in the tropics
Mental health in the tropics
Surgery in the tropics
Humanitarian emergency
Epidemiology in outbreak
Antimicrobial resistance
Pathology of infectious diseases
General issues of Travel med.
Epidemiology of Travel health
Last minute traveler
Time zone issue
High altitude medicine
Diving medicine
Pregnancy and travel
Children and travel
Elderly and travel
Immunology
Principle of human immune system
Innate immunity
Cellular immunity
Humoral immunity
Neutralizing antibody and its assay
Antigenic Cartography
Additional materials of immunology
Epi & Stats
Basics & Definition
Epidemiology
Odds in statistics and Odds in a horse race
Collider bias
Data distribution
Statistical test
Regression model
Multivariate analysis
Marginal effects
Prediction and decision
Table-related commands in STATA
Missing data and imputation
Virus
HIV
HIV-TB co-infection
HIV-STI interaction
Viral Hemorrhagic Fever
Ebola
Crimean-Congo hemorrhagic fever
SFTS
Rabies
Polio
Dengue
Yellow fever
Chikungunya
Zika
Japanese encephalitis
Tick-borne encephalitis
Viral hepatitis
Measles
Smallpox and Monkeypox
Respiratory Syncytial virus
COVID-19
Bivalent BA.1/BA.4-5 mRNA vaccines
Monovalent XBB-1.5 mRNA vaccine
Private archives of the initial phase of the pandemic
Private archives of lecture materials of COVID vaccine as of March 2021
厚生労働省が発出する保健行政関連の文書の読み解き方
Bacteria
Bacteriological tests
Tuberculosis
Tuberculosis in Children
HIV-TB co-infection
Leprosy
Dermatological mycobacterium infecions
Syphilis and Yaws
Plague
Pneumococcus
Meningococcus
Typhoid
Salmonellosis
Melioidosis
Leptospirosis
Brucellosis
Bartonellosis
Lyme disease and Relapsing fever
Tularaemia
Tetanus
Diphtheria
Anthrax
Coxiellosis
Rickettsia
Rickettsiosis
Scrub typhus
Spotted fevers
Epidemic typhus
Murine typhus
Protozoa
Overview of protozoa
Overview of medicine for protozoa
Malaria
Chagas disease
African trypanosomiasis
Leishmaniasis
Trichomoniasis
Toxoplasmosis
Amoebiasis
Giardiasis
Cryptosporidiosis
Cyclosporiasis
Isosporiasis
Pentatrichomoniasis
Microsporidiasis
Babesiosis
Fungi
General issues of fungi
Coccidioidomycosis
Paracoccidioidomycosis
Histoplasmosis
Talaromycosis
Blastomycosis
Sporotrichosis
Nematode (roundworm)
Nematode principles
Lympatic filariasis
Onchocerciasis
Loiasis
Microscopic differentiation of microfilariae
Strongyloidiasis
Ascariasis
Ancylostomiasis (hookworm)
Trichuriasis (whipworm)
Enterobiasis (pinworm)
Angiostrongyliasis (rat lungworm)
Dracunculiasis (Guinea worm)
Anisakiasis
Trichinellosis (Trichinosis)
Gnathostomiasis
Spirurinasis
Soil-transmitted helminths
Trematode (fluke, distoma)
General issues of Helminths
Trematode principles
Schistosomiasis
Clonorchiasis
Fascioliasis
Paragonimiasis
Metagonimiasis
Cestode (tapeworm)
General issues of Helminths
Cestode principles
Diphyllobothriasis
Sparganosis
Taeniasis
Echinococcosis
Medical Zoology
Zoonosis
Insectology
Mosquitology
Acarology
Batology
Snake toxicology
Scorpion and spider toxicology
Marine toxicology

Chevron-up-blue.png

epidemiology

  • 1.19mi. deaths in 2016
  • 197.05 mil. episodes in 2016
  • the leading cause of lower respiratory infections followed by H. influenzae, influenza /B and RS virus
  • 50% of pneumococcal deaths in India, Nigeria, DRC and Pakistan

serotype

  • all serotypes known more than 90 are pathogenic for human
  • differentiation of serotypes is important for epidemiology

antimicrobial resitance

  • first reported in late 1960s

Vaccine

  • PPSV does not induce T-cell dependent immunity
  • PCV induces T-cell dependent immunity
  • new product "Pneumosil" from India
    • 10-valent
    • serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 23F
  • the reason why PCV13 for older population failed to show persistent efficacy against IPD in the U.S. may be contributed by spread of PCV13 for children which has caused serotype substitutions in community

History of Pneumococcal vaccines in Japan

Table updated on 25th Aug 2023
Year PPSV23 PCV7 PCV13 PCV15 PCV20
Pneumovax NP Prevenar Prevenar13 Vaxneuvance
1988
昭和63
Approved
- 2yr≤
Covered by Public Health Insurance
- Asplenia
2009
平成21
Approved
- 2mo≤ ≤9yr
2010
平成22
Routinized
- 2mo≤ ≤60mo (<5yr)
2013
平成25
Terminated and switched to PCV13 Approved
- 2mo≤ <6yr
Routinized
- 2mo≤ ≤60mo (<5yr)
2014
平成26
Routinized
- at 65yr
- 60-64yr with specific chronic conditions
Approved
- 65yr≤ at risk of IPD
2020
令和2
Approved
- 6yr≤ at risk of IPD
2022
令和4
Approved
- elderly
- adults at risk of IPD
2023
令和5
Approved
- 2mo≤
Submitted for approval
PPSV23 PCV7 PCV13 PCV15 PCV20

Efficacy of pneumococcal vaccines

Effectiveness of pneumococcal vaccines

Effectiveness against colonization

Serotype replacement

Overwhelming Post-Splenectomy Infection (OPSI) and pnuemococcus